

Direct Reprogramming of Hepatic Myofibroblasts into Fibrosis

Cell Stem Cell

18, 797-808

DOI: [10.1016/j.stem.2016.01.010](https://doi.org/10.1016/j.stem.2016.01.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future?. <i>Stem Cell Investigation</i> , 2016, 3, 53-53.	1.3	1
2	Novel methods for the treatment of liver fibrosis using in vivo direct reprogramming technology. <i>Stem Cell Investigation</i> , 2016, 3, 92-92.	1.3	1
3	Antifibrotics in chronic liver disease: tractable targets and translational challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 328-340.	3.7	36
4	Hepatocytes induced from myofibroblasts in vivo. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 250-250.	8.2	0
5	Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming. <i>Human Gene Therapy</i> , 2016, 27, 962-970.	1.4	6
6	In Vivo Cellular Reprogramming: The Next Generation. <i>Cell</i> , 2016, 166, 1386-1396.	13.5	234
7	An easy method for preparation of Cre-loxP regulated fluorescent adenoviral expression vectors and its application for direct reprogramming into hepatocytes. <i>Biotechnology Reports (Amsterdam)</i> , 2016, 10, 1-10.	1.0	10
8	Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are key. <i>Hepatology International</i> , 2016, 10, 902-908.	1.9	34
9	Lineage tracing reveals conversion of liver sinusoidal endothelial cells into hepatocytes. <i>Development Growth and Differentiation</i> , 2016, 58, 620-631.	0.6	4
10	In Vivo Reprogramming for CNS Repair: Regenerating Neurons from Endogenous Glial Cells. <i>Neuron</i> , 2016, 91, 728-738.	3.8	131
11	Liver fibrosis: Which mechanisms matter?. <i>Clinical Liver Disease</i> , 2016, 8, 94-99.	1.0	15
12	Emerging advancements in liver regeneration and organogenesis as tools for liver replacement. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 581-587.	0.8	15
13	Treating Liver Fibrosis: (Re)Programmed to Succeed. <i>Cell Stem Cell</i> , 2016, 18, 683-684.	5.2	5
14	Human Pluripotent Stem Cells: Myths and Future Realities for Liver Cell Therapy. <i>Cell Stem Cell</i> , 2016, 18, 703-706.	5.2	14
15	Progress in stem cell-based therapy for liver disease. <i>Hepatology Research</i> , 2017, 47, 127-141.	1.8	32
16	Core Transcription Factors, MicroRNAs, and Small Molecules Drive Transdifferentiation of Human Fibroblasts Towards The Cardiac Cell Lineage. <i>Scientific Reports</i> , 2017, 7, 40285.	1.6	36
17	Reprogramming cell fates by small molecules. <i>Protein and Cell</i> , 2017, 8, 328-348.	4.8	82
18	In Vivo Interplay between p27Kip1, GATA3, ATOH1, and POU4F3 Converts Non-sensory Cells to Hair Cells in Adult Mice. <i>Cell Reports</i> , 2017, 19, 307-320.	2.9	133

#	ARTICLE	IF	CITATIONS
19	Cell fate modification toward the hepatic lineage by extrinsic factors. <i>Journal of Biochemistry</i> , 2017, 162, 11-16.	0.9	1
20	Hepatic stellate cells as key target in liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 27-42.	6.6	943
21	Assessment of engineered cells using CellNet and RNA-seq. <i>Nature Protocols</i> , 2017, 12, 1089-1102.	5.5	41
22	Engineering kidney cells: reprogramming and directed differentiation to renal tissues. <i>Cell and Tissue Research</i> , 2017, 369, 185-197.	1.5	17
23	Gli-fully Halting the Progression of Fibrosis. <i>Cell Stem Cell</i> , 2017, 20, 735-736.	5.2	7
24	The novel tool of cell reprogramming for applications in molecular medicine. <i>Journal of Molecular Medicine</i> , 2017, 95, 695-703.	1.7	19
25	Seeds in the liver. <i>Acta Histochemica</i> , 2017, 119, 349-356.	0.9	4
26	Gene regulatory networks in differentiation and direct reprogramming of hepatic cells. <i>Seminars in Cell and Developmental Biology</i> , 2017, 66, 43-50.	2.3	38
27	Specific Cell (Re-)Programming: Approaches and Perspectives. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2017, 163, 71-115.	0.6	3
28	Evaluating the regenerative potential and functionality of human liver cells in mice. <i>Differentiation</i> , 2017, 98, 25-34.	1.0	7
29	Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 737-752.	0.9	16
30	Advances in cancer stem cell targeting: How to strike the evil at its root. <i>Advanced Drug Delivery Reviews</i> , 2017, 120, 89-107.	6.6	58
31	Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1601-1610.e3.	0.4	20
32	A Scalable Approach for the Generation of Human Pluripotent Stem Cell-Derived Hepatic Organoids with Sensitive Hepatotoxicity Features. <i>Stem Cells and Development</i> , 2017, 26, 1490-1504.	1.1	40
33	Chemical Cocktails Enable Hepatic Reprogramming of Mouse Fibroblasts with a Single Transcription Factor. <i>Stem Cell Reports</i> , 2017, 9, 499-512.	2.3	30
34	In vivo reprogramming for tissue regeneration and organismal rejuvenation. <i>Current Opinion in Genetics and Development</i> , 2017, 46, 132-140.	1.5	31
35	Direct conversion of human fibroblasts into hepatocyte-like cells by ATF5, PROX1, FOXA2, FOXA3, and HNF4A transduction. <i>Scientific Reports</i> , 2017, 7, 16675.	1.6	54
36	Shp2 promotes liver cancer stem cell expansion by augmenting β -catenin signaling and predicts chemotherapeutic response of patients. <i>Hepatology</i> , 2017, 65, 1566-1580.	3.6	127

#	ARTICLE	IF	CITATIONS
37	Direct reprogramming of mouse fibroblasts into neural cells via Porphyra yezoensis polysaccharide based high efficient gene co-delivery. <i>Journal of Nanobiotechnology</i> , 2017, 15, 82.	4.2	7
38	A Roadmap for Human Liver Differentiation from Pluripotent Stem Cells. <i>Cell Reports</i> , 2018, 22, 2190-2205.	2.9	145
39	Engineering and Application of Pluripotent Stem Cells. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2018, , .	0.6	0
40	<i>Applied RNA Bioscience</i> . , 2018, , .		1
42	Applications of Virus Vector-Mediated Gene Therapy in China. <i>Human Gene Therapy</i> , 2018, 29, 98-109.	1.4	3
43	Gene therapy approaches in the non-human primate model of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 575-589.	1.4	20
44	Mechanisms of Renal Fibrosis. <i>Annual Review of Physiology</i> , 2018, 80, 309-326.	5.6	681
45	Liver cell therapy: is this the end of the beginning?. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1307-1324.	2.4	56
46	Monitoring cytochrome P450 activity in living hepatocytes by chromogenic substrates in response to drug treatment or during cell maturation. <i>Archives of Toxicology</i> , 2018, 92, 1133-1149.	1.9	6
47	Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 709-720.	1.8	34
48	The Potential Role of Stem Cell Reprogramming in Antiaging. , 2018, , 35-45.		2
49	Generation of Hepatocyte-Like Cells by Different Strategies for Liver Regeneration. <i>Nano LIFE</i> , 2018, 08, 1841004.	0.6	1
50	Impact of Three-Dimensional Culture Systems on Hepatic Differentiation of Puripotent Stem Cells and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1077, 41-66.	0.8	0
51	Prolonged inhibition of hepatocellular carcinoma cell proliferation by combinatorial expression of defined transcription factors. <i>Cancer Science</i> , 2018, 109, 3543-3553.	1.7	33
52	Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis. <i>Reproductive Medicine and Biology</i> , 2018, 17, 369-397.	1.0	35
53	Homologous recombination mediates stable Fah gene integration and phenotypic correction in tyrosinaemia mouse-model. <i>World Journal of Hepatology</i> , 2018, 10, 277-286.	0.8	10
54	Clinical applications of retinal gene therapies. <i>Precision Clinical Medicine</i> , 2018, 1, 5-20.	1.3	11
55	Highly Efficient Intracellular Protein Delivery by Cationic Polyethyleneimine-Modified Gelatin Nanoparticles. <i>Materials</i> , 2018, 11, 301.	1.3	27

#	ARTICLE	IF	CITATIONS
56	Bench to bedside: Current advances in regenerative medicine. <i>Current Opinion in Cell Biology</i> , 2018, 55, 59-66.	2.6	14
57	Reprogramming of Cells by Lactic Acid Bacteria. , 2018, , 47-61.		0
58	Exploration for Cell Sources for Liver Regenerative Medicine: "CLIP" as a Dawn of Cell Transplantation Therapy. , 2018, , 77-101.		0
59	Generation of Hepatocytes by Transdifferentiation. , 2018, , 103-114.		0
60	Current Advances in Red Blood Cell Generation Using Stem Cells from Diverse Sources. <i>Stem Cells International</i> , 2019, 2019, 1-10.	1.2	22
61	Oct4 and Hnf4 α -induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. <i>PLoS ONE</i> , 2019, 14, e0221085.	1.1	10
62	Liver stem cells: Plasticity of the liver epithelium. <i>World Journal of Gastroenterology</i> , 2019, 25, 1037-1049.	1.4	19
63	Strategies for in vivo reprogramming. <i>Current Opinion in Cell Biology</i> , 2019, 61, 9-15.	2.6	19
64	Space of Disse: a stem cell niche in the liver. <i>Biological Chemistry</i> , 2019, 401, 81-95.	1.2	20
65	Phenotypical and Functional Polymorphism of Liver Resident Macrophages. <i>Cells</i> , 2019, 8, 1032.	1.8	47
66	"Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 109-129.	0.9	4
67	TGF β ² Impairs HNF1 α Functional Activity in Epithelial-to-Mesenchymal Transition Interfering With the Recruitment of CBP/p300 Acetyltransferases. <i>Frontiers in Pharmacology</i> , 2019, 10, 942.	1.6	8
68	Toward a Reconceptualization of Stem Cells from Cellular Plasticity. <i>International Journal of Stem Cells</i> , 2019, 12, 1-7.	0.8	3
69	Design Approaches for Generating Organ Constructs. <i>Cell Stem Cell</i> , 2019, 24, 877-894.	5.2	26
70	Chemically induced cell fate reprogramming and the acquisition of plasticity in somatic cells. <i>Current Opinion in Chemical Biology</i> , 2019, 51, 146-153.	2.8	11
71	In Vivo Cell Conversion as a New Cell Therapy. <i>Current Human Cell Research and Applications</i> , 2019, , 169-190.	0.1	0
72	Medical Applications of iPS Cells. <i>Current Human Cell Research and Applications</i> , 2019, , .	0.1	0
73	Wound healing and fibrosis: current stem cell therapies. <i>Transfusion</i> , 2019, 59, 884-892.	0.8	24

#	ARTICLE	IF	CITATIONS
74	Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. <i>Molecular Aspects of Medicine</i> , 2019, 65, 37-55.	2.7	628
75	Innovation for hepatotoxicity in vitro research models: A review. <i>Journal of Applied Toxicology</i> , 2019, 39, 146-162.	1.4	16
76	Direct cellular reprogramming and inner ear regeneration. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 129-139.	1.4	17
77	Conversion of Fibroblasts to Hepatocyte-Like Cells In Vivo. <i>Methods in Molecular Biology</i> , 2019, 1905, 103-115.	0.4	0
78	The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis. <i>Stem Cell Research and Therapy</i> , 2019, 10, 21.	2.4	26
79	New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine. <i>Trends in Biotechnology</i> , 2019, 37, 604-617.	4.9	23
80	Antifibrotics in liver disease: are we getting closer to clinical use?. <i>Hepatology International</i> , 2019, 13, 25-39.	1.9	25
81	Hepatic regeneration by associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is feasible but attenuated in rat liver with thioacetamide-induced fibrosis. <i>Surgery</i> , 2019, 165, 345-352.	1.0	7
82	Ex Vivo/In Vivo Gene Editing in Hepatocytes Using "All-in-One" CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. <i>iScience</i> , 2020, 23, 100764.	1.9	33
83	Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 3-32.	1.7	292
84	Wnt4 negatively regulates the TGF- β 1-induced human dermal fibroblast-to-myofibroblast transition via targeting Smad3 and ERK. <i>Cell and Tissue Research</i> , 2020, 379, 537-548.	1.5	28
85	Epithelial Plasticity during Liver Injury and Regeneration. <i>Cell Stem Cell</i> , 2020, 27, 557-573.	5.2	72
86	Down-regulation of Beclin1 promotes direct cardiac reprogramming. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	41
87	Overview of Tissue Engineering Concepts and Applications. , 2020, , 1289-1316.		4
88	Fibrosis: from mechanisms to medicines. <i>Nature</i> , 2020, 587, 555-566.	13.7	746
89	The Dynamics of Transcriptional Activation by Hepatic Reprogramming Factors. <i>Molecular Cell</i> , 2020, 79, 660-676.e8.	4.5	42
90	Integrated Analyses of Mouse Stem Cell Transcriptomes Provide Clues for Stem Cell Maintenance and Transdifferentiation. <i>Frontiers in Genetics</i> , 2020, 11, 563798.	1.1	3
91	Direct reprogramming of mouse fibroblasts into hepatocyte-like cells by polyethyleneimine-modified nanoparticles through epigenetic activation of hepatic transcription factors. <i>Materials Today Chemistry</i> , 2020, 17, 100281.	1.7	4

#	ARTICLE	IF	CITATIONS
92	Extensively expanded murine α -induced hepatic stem cells maintain high α -efficient hepatic differentiation potential for repopulation of injured livers. <i>Liver International</i> , 2020, 40, 2293-2304.	1.9	6
93	Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?. <i>Cells</i> , 2020, 9, 566.	1.8	14
94	The control of conjunctival fibrosis as a paradigm for the prevention of ocular fibrosis-related blindness. α “Fibrosis has many friends α ”. <i>Eye</i> , 2020, 34, 2163-2174.	1.1	18
95	Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine. <i>Advanced Functional Materials</i> , 2020, 30, 1909553.	7.8	28
96	Engineering Biomaterials with Micro/Nanotechnologies for Cell Reprogramming. <i>ACS Nano</i> , 2020, 14, 1296-1318.	7.3	39
97	Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?. <i>Frontiers in Pharmacology</i> , 2020, 11, 548.	1.6	31
98	Direct cell-fate conversion of somatic cells: Toward regenerative medicine and industries. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2020, 96, 131-158.	1.6	22
99	The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction. <i>Theranostics</i> , 2021, 11, 5539-5552.	4.6	3
100	Repair and Regeneration After Important Visceral Injury. , 2021, , 193-282.		0
101	On the origins and conceptual frameworks of natural plasticity α ”Lessons from single-cell models in <i>C. elegans</i> . <i>Current Topics in Developmental Biology</i> , 2021, 144, 111-159.	1.0	9
102	Synergistic control of mechanics and microarchitecture of 3D bioactive hydrogel platform to promote the regenerative potential of engineered hepatic tissue. <i>Biomaterials</i> , 2021, 270, 120688.	5.7	11
103	Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat. <i>Chinese Medicine</i> , 2021, 16, 27.	1.6	9
104	Generation of mature and functional hair cells by co-expression of Gfi1, Pou4f3, and Atoh1 in the postnatal mouse cochlea. <i>Cell Reports</i> , 2021, 35, 109016.	2.9	63
105	Direct conversion of porcine primary fibroblasts into hepatocyte-like cells. <i>Scientific Reports</i> , 2021, 11, 9334.	1.6	4
106	Preclinical Application of Reduced Manipulated Processing Strategy to Collect Transplantable Hepatocytes: A Pilot and Feasibility Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 326.	1.1	1
107	Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification. <i>Archives of Toxicology</i> , 2021, 95, 2413-2430.	1.9	2
108	Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. <i>Annual Review of Biomedical Engineering</i> , 2021, 23, 517-546.	5.7	9
109	In vivo reprogramming as a new approach to cardiac regenerative therapy. <i>Seminars in Cell and Developmental Biology</i> , 2022, 122, 21-27.	2.3	12

#	ARTICLE	IF	CITATIONS
110	Perivascular stromal cells: Directors of tissue immune niches. <i>Immunological Reviews</i> , 2021, 302, 10-31.	2.8	14
111	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. <i>Wound Repair and Regeneration</i> , 2021, 29, 678-691.	1.5	20
112	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	2.2	27
113	Fibroblasts: Origins, definitions, and functions in health and disease. <i>Cell</i> , 2021, 184, 3852-3872.	13.5	340
114	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113831.	6.6	17
115	Direct reprogramming of somatic cells into induced hepatocytes: Cracking the Enigma code. <i>Journal of Hepatology</i> , 2021, 75, 690-705.	1.8	15
116	Stationed or Relocating: The Seesawing EMT/MET Determinants from Embryonic Development to Cancer Metastasis. <i>Biomedicines</i> , 2021, 9, 1265.	1.4	10
117	Reprogramming toward kidney regeneration: New technologies and future promises. , 2022, , 379-394.		0
118	Cellular Basis for Tissue Regeneration: Cellular Dedifferentiation. , 2021, , 57-76.		0
119	Generation of hepatocyte-like cells from human urinary epithelial cells and the role of autophagy during direct reprogramming. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 723-729.	1.0	8
120	Direct cell reprogramming: approaches, mechanisms and progress. <i>Nature Reviews Molecular Cell Biology</i> , 2021, 22, 410-424.	16.1	178
122	GATA4-dependent organ-specific endothelial differentiation controls liver development and embryonic hematopoiesis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1099-1114.	3.9	102
123	Resolution of organ fibrosis. <i>Journal of Clinical Investigation</i> , 2018, 128, 97-107.	3.9	245
124	Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis. <i>F1000Research</i> , 2016, 5, 1749.	0.8	16
125	Loss-of-function mutations in Zn-finger DNA-binding domain of <i>HNF4A</i> cause aberrant transcriptional regulation in liver cancer. <i>Oncotarget</i> , 2018, 9, 26144-26156.	0.8	17
126	Generated Hepatocyte-Like Cells: A Novel Tool in Regenerative Medicine and Drug Discovery. <i>Cell Journal</i> , 2017, 19, 204-217.	0.2	16
127	Impelling force and current challenges by chemicals in somatic cell reprogramming and expansion beyond hepatocytes. <i>World Journal of Stem Cells</i> , 2019, 11, 650-665.	1.3	4
128	Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. <i>Cells</i> , 2021, 10, 2759.	1.8	73

#	ARTICLE	IF	CITATIONS
129	Introduction to In Vivo Cell Reprogramming Technology. <i>Pancreatic Islet Biology</i> , 2017, , 1-10.	0.1	0
133	Stem cells and regenerative medicine. , 2020, , 281-295.		0
134	Direct Conversion of Cell Fate and Induced Endothelial Cells. <i>Circulation Journal</i> , 2021, , .	0.7	0
135	Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2020, 26, 3917-3928.	1.4	10
136	Early oleate deficiency leads to severe defects in fetal rat liver development. <i>Iranian Journal of Basic Medical Sciences</i> , 2019, 22, 1010-1015.	1.0	2
137	NMDA receptor expression during cell transformation process at early stages of liver cancer in rodent models. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G142-G153.	1.6	3
138	Alleviation of Liver Fibrosis Via Hepatic Stellate Cells Mitochondrial Apoptosis Induced by Metformin. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
139	TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth. <i>Communications Biology</i> , 2022, 5, 42.	2.0	1
140	Cell reprogramming in liver with potential clinical correlations. <i>Journal of Digestive Diseases</i> , 2022, 23, 13-21.	0.7	2
141	HNF4A Regulates the Proliferation and Tumor Formation of Cervical Cancer Cells through the Wnt/ β -Catenin Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-17.	1.9	5
142	Reprogramming the spleen into a functioning "liver" in vivo. <i>Gut</i> , 2022, 71, 2325-2336.	6.1	9
143	Transdifferentiation Meets Next-generation Biotechnologies. <i>StemJournal</i> , 2022, 4, 1-11.	0.8	1
144	Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis. <i>Frontiers in Pharmacology</i> , 2022, 13, 787748.	1.6	26
145	Reprogramming cellular identity <i>in vivo</i> . <i>Development (Cambridge)</i> , 2022, 149, .	1.2	14
146	Novel integrated workflow allows production and in-depth quality assessment of multifactorial reprogrammed skeletal muscle cells from human stem cells. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 229.	2.4	3
147	Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin. <i>International Immunopharmacology</i> , 2022, 108, 108683.	1.7	4
156	Limitations and challenges of direct cell reprogramming in vitro and in vivo.. <i>Histology and Histopathology</i> , 2022, , 18458.	0.5	2
158	CD73 Aggravates Alcohol-Related Liver Fibrosis by Promoting Autophagy Mediated Activation of Hepatic Stellate Cells Through Ampk/Akt/Mtor Signaling Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
160	Wound healing, fibroblast heterogeneity, and fibrosis. <i>Cell Stem Cell</i> , 2022, 29, 1161-1180.	5.2	116
161	Direct Reprogramming in Bone and Joint Degenerative Diseases: Applications, Obstacles and Directions.. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, .	0.6	0
162	Preparation of Functional Human Hepatocytes Ex Vivo. <i>Methods in Molecular Biology</i> , 2022, , 269-278.	0.4	1
163	CD73 aggravates alcohol-related liver fibrosis by promoting autophagy mediated activation of hepatic stellate cells through AMPK/AKT/mTOR signaling pathway. <i>International Immunopharmacology</i> , 2022, 113, 109229.	1.7	3
164	Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	10
165	Fibroblast Activation Protein Activates Macrophages and Promotes Parenchymal Liver Inflammation and Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 841-867.	2.3	19
166	Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. <i>Hepatology</i> , 2023, 78, 1625-1653.	3.6	2
168	Depletion of <i>Tgfb2</i> in hepatocytes alleviates liver fibrosis and restores hepatic function in fibrotic mice. <i>Journal of Digestive Diseases</i> , 2023, 24, 39-50.	0.7	1
169	Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis. <i>Thorax</i> , 2023, 78, 682-689.	2.7	3
170	Fibroblasts: New players in the central nervous system?. <i>Fundamental Research</i> , 2024, 4, 262-266.	1.6	1
173	Stem cells in the management of phospholipase-mediated metabolic disorders. , 2023, , 3-23.		0